GleamWall
中文EN

IVA Inventiva S.A. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1756594 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY43.5%
TTM net income YoY-103.5%
TTM EPS YoY-85.5%
Revenue 3-yr CAGR260.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-587.7%
Net margin-631.8%
FCF margin—
EBITDA margin—

Returns

ROE-1,642.8%
ROA-119.0%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets146.0%
Debt / equity—
Current ratio0.96x
Interest coverage-19.84x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-31.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue9.20M17.48M
R&D expense90.88M110.01M
SG&A expense15.84M13.84M
Operating income-97.56M-102.71M
Interest expense12.18M5.18M
Income tax313,000607,000
Net income-184.21M-110.43M
EPS (basic)-3.08-2.43
EPS (diluted)-3.08-2.43
Weighted avg. shares (diluted)59.78M45.35M
Balance sheet
Cash & equivalents96.56M26.92M
Short-term investments—10,000
Receivables531,0003.81M
Inventory0417,000
Current assets111.51M48.19M
PP&E, netmay include right-of-use assets (IFRS)5.00M9.12M
Intangibles48,000541,000
Total assets118.97M69.56M
Current liabilities120.73M50.16M
Total liabilities225.61M101.59M
Shareholders' equity-106.65M-32.03M
Shares outstanding95.66M52.12M
Cash flow statement
Operating cash flow-85.93M-81.61M
Investing cash flow8.74M-7.73M
Financing cash flow145.59M29.08M
Stock-based compensation3.58M3.97M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.